CA2450779C - Powder formation by atmospheric spray-freeze drying - Google Patents
Powder formation by atmospheric spray-freeze drying Download PDFInfo
- Publication number
- CA2450779C CA2450779C CA2450779A CA2450779A CA2450779C CA 2450779 C CA2450779 C CA 2450779C CA 2450779 A CA2450779 A CA 2450779A CA 2450779 A CA2450779 A CA 2450779A CA 2450779 C CA2450779 C CA 2450779C
- Authority
- CA
- Canada
- Prior art keywords
- flow
- chamber
- coolant
- liquid droplets
- frozen particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000843 powder Substances 0.000 title claims abstract description 62
- 238000004108 freeze drying Methods 0.000 title claims description 29
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 239000007788 liquid Substances 0.000 claims abstract description 77
- 239000002245 particle Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims description 53
- 239000002826 coolant Substances 0.000 claims description 37
- 238000001035 drying Methods 0.000 claims description 24
- 239000007921 spray Substances 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 20
- 238000005507 spraying Methods 0.000 claims description 17
- 238000007710 freezing Methods 0.000 claims description 14
- 230000008014 freezing Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 238000000151 deposition Methods 0.000 claims 3
- 230000008021 deposition Effects 0.000 claims 2
- 230000005484 gravity Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 44
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 22
- 239000007789 gas Substances 0.000 abstract description 20
- 239000012530 fluid Substances 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 6
- 238000001816 cooling Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000725 suspension Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 11
- 239000000112 cooling gas Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 238000005057 refrigeration Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000000859 sublimation Methods 0.000 description 5
- 230000008022 sublimation Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000012809 cooling fluid Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- SAJGCUXAHBJVRH-MVNLRXSJSA-N (2r,3r,4r,5r)-hexane-1,2,3,4,5,6-hexol;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SAJGCUXAHBJVRH-MVNLRXSJSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
- B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
- F26B5/065—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Drying Of Solid Materials (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Glanulating (AREA)
- Medicinal Preparation (AREA)
Abstract
A method of manufacturing heat-sensitive pharmaceutical powder is disclosed. The original pharmaceutical substances are dissolved in a solution or suspended in a suspension, which is sprayed through an atomizing nozzle and frozen in a cold gas phase or liquid nitrogen atomized directly in the spray-freeze chamber or gas jacket at the same time (for cooling purposes). The particles are freeze-dried at roughly atmospheric pressure in a down-stream fluid flow with exit filter thereby to remove moisture entrapped on or inside the frozen particles. The system has applicability for forming other powders.
Description
PONDER FORMATION BY ATMOSPHERIC SPR.~Y-FREEZE DRYING
BACKGROUND OF THE INVENTION
O1 This invention relates to the preparation of powders, particularly for the administration of pharmaceuticals to humans.
02 Pharmaceuticals are often unstable compounds that degrade rapidly during pracesses that lead to a powder form of the pharmaceutical. Since the pharmaceutical compound is usually carried in an aqueous solution, and the aqueous solution must be dried to form the powder, the required desiccation or drying process may easily damage the pharmaceutical.
At the same time, if the process of forming the powder takes too long, or is too energy consuming, the process may become uneconomic.
03 Freeze drying (lyophilization), which has conventionally been used to prepare pharmaceutical powders, provides a two step preservation and dehydration process in which the product is first frozen and the water is then removed as vapor from the frozen state. As the water passes from the solid phase directly into the vapor phase, it is necessary that the vapor pressure and the temperature of the sublimation zone is held below those of the triple point on the phase diagram for water. The temperature («0°C) and the maintenance of the frozen state lead to very low driving forces for heat and mass transfer and therefore, often to very low drying rates and very long drying times. Thus, despite its capability of providing a very high-quality dehydrated product, freeze-drying has been and remains highly energy-intensive and consequently, is a very expensive dehydration process.
04 Freeze drying conventionally is carried out in a vacuum, but may also be carried out at or near atmospheric pressure. Atmospheric freeze-drying has been shown to have the added advantage of increasing transfer coefficients and improving the uniformity of the product during lyophilization. For example, Meryman, H. T., Sublimation freeze-drying without vacuum.
Sczerece, 130 (1959) 628-629 proposed an atmospheric freeze-drying process in which the partial pressure of water in the drying chamber is held at very low value and he suggested that such a process should be based on the principle of connective freeze drying, i.e. a cold air steam, kept dry by a molecular sieve desiccant or by a refrigerated condenser, should be circulated. More recently, i,euenberger, H., Spray freeze-drying ---the process of choice for low water soluble
BACKGROUND OF THE INVENTION
O1 This invention relates to the preparation of powders, particularly for the administration of pharmaceuticals to humans.
02 Pharmaceuticals are often unstable compounds that degrade rapidly during pracesses that lead to a powder form of the pharmaceutical. Since the pharmaceutical compound is usually carried in an aqueous solution, and the aqueous solution must be dried to form the powder, the required desiccation or drying process may easily damage the pharmaceutical.
At the same time, if the process of forming the powder takes too long, or is too energy consuming, the process may become uneconomic.
03 Freeze drying (lyophilization), which has conventionally been used to prepare pharmaceutical powders, provides a two step preservation and dehydration process in which the product is first frozen and the water is then removed as vapor from the frozen state. As the water passes from the solid phase directly into the vapor phase, it is necessary that the vapor pressure and the temperature of the sublimation zone is held below those of the triple point on the phase diagram for water. The temperature («0°C) and the maintenance of the frozen state lead to very low driving forces for heat and mass transfer and therefore, often to very low drying rates and very long drying times. Thus, despite its capability of providing a very high-quality dehydrated product, freeze-drying has been and remains highly energy-intensive and consequently, is a very expensive dehydration process.
04 Freeze drying conventionally is carried out in a vacuum, but may also be carried out at or near atmospheric pressure. Atmospheric freeze-drying has been shown to have the added advantage of increasing transfer coefficients and improving the uniformity of the product during lyophilization. For example, Meryman, H. T., Sublimation freeze-drying without vacuum.
Sczerece, 130 (1959) 628-629 proposed an atmospheric freeze-drying process in which the partial pressure of water in the drying chamber is held at very low value and he suggested that such a process should be based on the principle of connective freeze drying, i.e. a cold air steam, kept dry by a molecular sieve desiccant or by a refrigerated condenser, should be circulated. More recently, i,euenberger, H., Spray freeze-drying ---the process of choice for low water soluble
2 drugs, Journal of Nanoparticle Research, 4:111-119, 2002 has also identified that spray freeze drying helps preserve pharmacological activity of drugs by stabilization in an appropriate matrix.
OS Despite the potential advantages of atmospheric lyophilization, the challenge still remains to provide a combination of spray-freezing solutionlsuspension into liquid and atmospheric freeze-drying that meets industrial demands for a pharmaceutical powder process that maintains drug bioactivity at low economic cost.
SUMMARY ~F THE INVENTICJN
06 It is therefore an object of this invention to provide atmospheric spray freeze drying of liquid carrying pharmaceuticals to produce a powder by a pharmaceutical powder process that maintains drug bioactivity at low economic cost. The invention provides a method of manufacturing a powder or particulate pharmaceutical substance, and an apparatus for carrying out the method. The powder produced by this process is believed to exhibit higher emitted dose and better preservation of bioactivity than spray-dried particles and milled particles. In addition, the porous nature of the particles provides rapid dissolution properties. The invention is applicable to the formation of other powders, including powder forms of nutraceuticals and foods.
07 Therefore, according t~ an aspect of the invention, there is provided a method of creating a powder, comprising spraying a carrier liquid containing a pov~der forming ingredient to forth a flow of liquid droplets; entraining the flow with a coolant for sufficient time to freeze the liquid droplets into frozen particles; and drying the frozen particles to fbrm a dry powder.
08 According to a further aspect of the invention, there is provided apparatus for atmospheric spray freeze drying of an ingredient carrying liquid to form a powder, the apparatus comprising: a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid t~ produce a flow of liquid droplets; a nozzle system for providing a flow of coolant that entrains atomized fluid sprayed by the atomaizer; a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the fl~w of coolant before contact with the collector.
09 The powder forming ingredient may be suspended or dissolved in the carrier liquid. 'The entraining flow may be a concurrent flow of coolant, for example as sprayed from a ring nozzle or through porous side walls of a confining chamber. Frozen particles are preferably collected on a filter at an exit from the confining chamber, and drying mostly takes place on the filter. For enhanced drying, the flow over the filter should be at a warmer temperature than for freezing.
More than one powder forming ingredient may be l3resent in the carrier liquid.
Other aspects of the invention appear in the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
11 There will now be described preferred embodiments of the irmention with reference to the figures, by way of example, and without intending to limit the scope of the invention to the precise examples disclosed here, and in which figures:
Fig. 1 shows a first embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention;
Fig. 2 shows a second embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention; and Fig. 3 shows a third embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENT S OF THE INVENTION
12 The word "comprising" in the claims is used in its inclusive sense and does not exclude other elements being present. The use of the indefinite article "a" in a claim before an element does not exclude more than one ofthe element being present.
13 The present invention is widely applicable for producing particulate material and can be used for spray-freeze drying any material amenable to dissohztion or suspension in a suitable carrier liquid, such as water. The term powder forming ingredient is used to refer to one or more pharmaceutical, nutraceutical, food or other substances that have utility in powder form. 'The present invention is especially useful for heat-sensitive substances, such as proteins, nucleic acids, oligonucleotides, enzymes, liposomes, lipids, lipid complexes, anti-virals and vaccines (e.g. involving nonvirulent or attenuated pathogens), carbohydrates, polymers, polysaccharides, and peptides. However, its use is not limited to only large molecules, since the Yraethod always produces a powder from any material dissolved or suitably suspended in water;
it may be used to create, for example, powder anti-infectives, anti-microbials, anti-inflammatories, antineoplastics, analgesics, anaesthetics, cholinergics, adrenergics, anticonvulsants, anti-depressants, sedatives, tranquilizers and antiemetics, ixnmunosuppressives and immunostimulants, antihistamines, hormones, antivenoms and antitoxins. Cryoprotectants may be added to aid in preventing degradation of substances during processing. 'The ingredient carrying liquid may contain several different drugs arid also excipient material. For example, the particles may be made mostly out of lactose with only a little drug in them. Gr there may be several drags in the ingredient carrying liquid, plus lactose or other filler/matrixJexcipient compound.
14 In the embodiments shown in Figs. l, 2 and 3, a flow or spray of atomized carrier fluid is frozen into a powder of solid particles by an entraining flow of coolant and subsequently dried by providing a flow of desiccating gas over the powder. Entraining by the cooling gas provides for confining the spray, and immediate freezing of the individual spray droplets, so that the liquid spray droplets do not impact on the walls of the chamber in which the process is carried out.
15 Referring to the first eanbodiment shown in Fig. 1, a housing 100 formed with solid insulated walls supports at an inlet end an atomizer 102 that is supplied through line 104 with compressed gas from source 106 and a suitable carrier liquid from source I08.
Inside the housing 100 is a flow chamber A 10 with porous walls. 'The flow chamber 110 is formed of cylindrical sections 112, 114 of differing diameter joined by a, con.icai section 116. Multiple nozzles 118 of a nozzle system penetrate the housing 100 arid supply a cryogenic flow of coolant from a coolant source 120 into the space between the housing 100 and flow chamber 110. At the other, exit, end of the housing 100 from the atomizer 102, the ~:'!ow chamber 110 terminates in a filter 122 that is held across an opening in the housing 100 by ~ plate 124 fixed to the chamber 100 by bolts or clamps 126 with ~-ring i28. Gas flow from the exit end of the housing 100 is returned to a refrigerated condenser that forms part of the coolant souxce 120. The refrigerated condenser strips moisture from the cooling gas for re-use of the cooling gas.
16 Referring to a second embodiment shown in Fig. 2, a housing 200 formed with solid insulated walls supports at an inlet end an atomizer 202 that is supplied through line 204 with compressed gas from source 206 and a suitable carrier liquid from source 208.
Inside the housing 200 is a flow chamber 210 defined by solid walls lining the housing 200. The flow chamber 210 is formed of cylindrical sections 212, 214 of differing diameter joined by a conical section 216. Surrounding the atomizer 202 is a nozzle system in the form of a ring nozzle 218, with openings 219 directing flow from the ring nozzle 218 parallel to flow from the atomizer 202. The ring nozzle 218 supplies a cryogenic flow of coolant from a coolant source 220, for example a Iiquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 202 in the spray-freezing step and a refrigerated condenser in the following drying step.
At the other, exit, end of the l~.ousing 200 from the atomizer 202, the flow chamber 210 terminates in a filter 222 that is held across an opening in the housing 200 by a plate 224 fixed to flanges 225 on the chamber 200 by bolts or clamps 226 with O-ring 228.
17 Referring to a third embodiment shown in fig. 3, a housing 300 formed with solid insulated walls supports at an inlet end an atomizer 302 that is supplied through line 304 with compressed gas from source 306 and a suitable carrier liquid from source 308.
Inside the housing 300 is a cylindrical flow chamber 310 defined by solid walls lining the housing 300.
Surrounding the atomizer 302 is a ring nozzle 318, with openings 319 directing flow from the ring nozzle 318 parallel to flow from the atomizer :302. T'he ring nozzle 318 supplies a cryogenic flow of coolant from a coolant source 320, for example a liquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 302 in the spray-freezing step and a refrigerated condenser in the following drying step. At the other, exit, end of the housing 300 from the atomizer 302, the flow chamber 310 terminates in a filter 322 that is held across an opening in the housing 300 by a plate 324 fixed to flanges 32~ on the chamber 300 by bolts or clamps 326 with O-ring 328.
18 The coolant source 120, 220 or 320 nay be any source of a coolant that does not contaminate or degrade the powder. Cold gas may be used such as refrigerated nitrogen, particularly for the embodiment shown in Fig. 1. The nitrogen may also be obtained from a liquid nitrogen cylinder driven by compressed gas, particularly for the embodiment shown in Figs. 2 and 3. Upon exiting the nozzles 118, 218 and 318, cold gas or liquid, for example cold liquid nitrogen or cold gaseous nitrogen, which may be sourced from a cylinder of liquid nitrogen or other cryogenic source of nitrogen, will entrain the spray and freeze the liquid drops of the spray. For freezing followed by drying, both a liquid nitrogen source and a refrigeration unit may be used. Freezing may be carried out using the liquid nitrogen source, as in the embodiment of Figs. 2 and 3, and then drying may be carried out at warmer temperatures using the refrigeration unit.
19 During manufacture, pharmaceutical agents (PA) or other powder forming ingredients are mixed with a carrier liquid prior to spraying from the atomizer 102, 202, 302.
The spray fluid resulting from the mixture of PA sand carrier liquid may be, for example, a solution, a suspension or a colloid. The atomizer 102, 202, 302 may be a two-fluid nozzle or an ultrasonic nebulizer or a vibrating orifice aerosol generator (VGAG) or other atomizing device. The spray fluid, which is formed of liquid droplets, is rapidly frozen through contact with coolant, which is a cold fluid of a suitable temperature. In the spray-freeze step, cooling fluid may be supplied in several possible ways. ~ne way, shown in Figs. 2, 3, is to spray cooling liquid such as liquid nitrogen directly into the chamber 200,300 by using the ring nozzle 218, 318, while spray droplets from atomizer 202, 302 inside the perimeter of the ring nozzle 218, 318 are frozen immediately after contacting the surrounding curtain of liquid nitrogen and then conveyed to the exit filter 222, 322 at the exit end of the housing 200, 300. Another way, shown in Fig. I, is to have a cooling gas enter through porous walls 112, 114, 116 that enclose the atomizer 102. Gas supplied into the space between the housing I00 and chamber 1I0 forms a gas jacl~et whose temperature is adjusted by mixing with liquid nitrogen or an equivalent cryogenic at different ratios.
20 In the example of Figs. 2 and 3, the curtain of spraying liquid nitrogen is used for freezing the spraying liquid droplets and avoiding cohesion oi" frozen powder on the sidewalk 210, 310. The spraying velocity and quantity of liquid nitrogen is controlled to meet both the cooling demand of the spray-freeze process and conveying of frozen powders to the exit filter 222, 322. In the example of Fig. 1, the flow passing through the porous sidewalk of the freezing chamber 110 has the same function as the spraying curtain of liquid nitrogen, i.e. reducing the particle cohesion and allowing a distinguishangly radial flow of cooling fluid into the chamber 110 to freeze liquid droplets and protect the liquid droplet/fro:zen particles from contacting the wall surface. The thickness of the porous sidewall 110 and pressure inside the gas jacleet, which is controlled by the flow rate of cooling gas into the chamber 100, are adjusted for the particular powder being processed. Thereafter, a down-flow transport by ~~irtue of the spray direction of the atomizer 102 is automatically formed in the spray-freeze process to carry all the frozen powder to the exit end of the chamber 100.
2 i After the accomplishment of spray-freezing, a proper drying temperature will be chosen in a drying step by flow rate adjustment from the cooling cryogenic or refrigeration system. In the meantime, the initial frozen powder collected on the exit filter 122, 222, 322 at exit end (bottom) of the chamber will be dried by sublimation in a cold desiccated airstream at atmospheric pressure.. Because all the frozen powder falls down or is conveyed by the down stream flow to the exit filter, no matter whether it is cohesive powder or free flow powder, no external forces are needed to re-lift the powder adhering on the walls, unlike in the spray-freeze drying process of a traditional up-stream fluidized bed, which are used in other processes like US
Patent 4,608,764.
22 In addition, less contamination is realized through this invention by screening frozen powder from contacting the sidewalk of the chamber 110, 21.0, 310 compared to the former technology. As the sublimation process is taking place, the frozen particles become lighter and the aerodynamic behavior changes. The partially dried particles may form a loose cake on the exit filter 122, 222, 322, from which the remaining moisture is removed by atmospheric sublimation using a cold desiccated gas stream, resulting in final free-flowing powders. After spray-freeze atmospheric drying, dry porous particles of xoughly the same size and shape as the original frozen droplets are obtained.
23 Spray freeze atmospheric dried particles produced by this method can have a morphology desirable for respiratory administration of medicament using respiratory delivery devices such as those disclosed in United States Patent Application US60430085 filed Nov. 27, 2003. The typically porous nature of particles formed from this process is also desirable for rapid dissolution, as seen in the BioAqueous technology from I7ow Cb.emical Company, as well as for other purposes such as those disclosed in e.g. United States Patent No.
6,635,283.
OPERATING PROCEDURES
24 The apparatus is allowed to run for approximately 5 to 30 minutes to reach the desired temperature in the chamber I 10, 210, 3I0 either by spraying liquid nitrogen directly into it, or by having the cold fluid from a refrigeration system flow into the chamber 110 through the porous wall. The aqueous solution or suspension of the substances to be dried is then sprayed using the atomizer 102, 202, 302 and frozen simultaneously in situ at a chosen temperature by the surrounding curtain of liquid nitrogen generated from ring nozzle 218, 318 or an equivalent such as cryogenic flow from nozzles 118 through porous sidewalk of chamber 110. The frozen powder is conveyed down to the exit filter I22, 222, 322 by the concurrent downstream flow.
After completion of the spray-freezing process, the flow of the cryogenic flLiid (at a low temperature of -50°C to -196°C) is shut off and switched to a cooling gas at a somewhat higher temperature (-10°C to -30°C) from the refrigeration system. Then the frozen powder collected on the exit filter 122, 222, 322, at the bottom is dried continuously by sublimation at atmospheric pressure until the remaining moistrare of the frozen powder is removed by the cold desiccated gas stream. After spray-freeze atmospheric drying, a noose cake occurs on the exit filter 122, 222, 322, which is very fragile and easily broken into free flowing, dry porous particles of approximately the same size and shape as the original frozen droplets. In order to reduce moisture condensation on the cold particle surface, the temperature of the desiccant cooling gas will be raised to room temperature gradually before the sample is collected from the chamber 100, 200, 300.
25 In one example, powder was produced using the method described above. A
l5wt%
mannitol solution was spray freeze-dried using the apparatus shown in Fig. 1.
A 15 % mannitol (Mannitol USP powder, Fisher Scientific) aqueous solution was used to demonstrate the process.
Before spraying, the chamber 110 for spray-freeze drying was allowed to nzn for approximately 20 minutes to reach the desired tegnperature (-65°C). During the 20 minutes, the cold fluid from a refrigeration unit incorporating two parallel dry-ice cooling columns flows into the chamber IIO through the porous sidewall. A Chem-Tech pump (Model CTPA4LSA-PAPI-XXXX, Viking pump of Canada Inc, Windsor, Ontario, Canada) was used to pump 20 mI of 15%
mannitol solution into an air atomizing spray nozzle 102 (Spraying Systems Co., Wheaton, Illinois, USA) spraying into the chamber from the top with the aid of a compressed driving gas (nitrogen) at a flowrate of 0.6 SCF1VI. The spray-freezing process was finished within 4 minutes and meanwhile, the temperature in the chamber 110 was kept at -50°C to -70°C by the mixed cooling gas (nitrogen). In this case, the pressure in the chamber was almost atmospheric (around 1.02 atm). After the completion of spray-freeze process, the pump and driving gas for spraying was shut down and the cooling gas for drying was kept Ilowir~g at a flowrate of 60 L/min. The temperature in the chamber was kept at around -lj°C (-~°C to -20°C) by adjusting the height of dry ice in the cooling columns. After drying for 1 hr, the temperature in the chamber was raised to room temperature gradually within another 30 minutes at a flowrate of 30 L/min. T hereafter, the cooling gas was shut off and a dry powder cake on the exit filter 122 was collected. This sake was easily broken into a free-flowing po order and the resulting particles were found very porous and roughly spherical. The moisture content was measured to be only 0.9%.
Photos from a scanning electron microscope (S~ll~d) of one resulting sample powder collected from the exit filter showed that the powder particles are relatively spherical and considerably porous, which is often seen in spray-freeze drying with vacuum.
26 Mannitol has been spray-frozen by us at -50°C to -70°C and dried in a temperature of -5°C to -20°C in order to avoid mannitol crystallization (mannitol hydrate occurs at around 38°C).
Based on practical demand (each bio-substance may have its ideal spray-freeze and drying temperature), the spray-freeze drying conditions are adjustable by changing the temperature and flow rate of the mixed cold gases. Depending on the batch scale, these parameters may be different.
27 For atmospheric pressure freeze drying with dry air, the temperature at which material may be truly freeze dried is set by its melting point. Since the vapor presswe of ice is essentially fixed by the melting point temperature, the rate of freeze-drying is essentially controlled by the resistance to water vapor diffusion in the material. This resistance is proportional to the diffusion path length and the permeability of the material. Atmospheric pressure freeze-drying should therefore be feasible in a wide variety of materials where diffizsion distances are very short in materials of open structure.
28 Immaterial modifications array be made to the invention described here without departing from the invention.
OS Despite the potential advantages of atmospheric lyophilization, the challenge still remains to provide a combination of spray-freezing solutionlsuspension into liquid and atmospheric freeze-drying that meets industrial demands for a pharmaceutical powder process that maintains drug bioactivity at low economic cost.
SUMMARY ~F THE INVENTICJN
06 It is therefore an object of this invention to provide atmospheric spray freeze drying of liquid carrying pharmaceuticals to produce a powder by a pharmaceutical powder process that maintains drug bioactivity at low economic cost. The invention provides a method of manufacturing a powder or particulate pharmaceutical substance, and an apparatus for carrying out the method. The powder produced by this process is believed to exhibit higher emitted dose and better preservation of bioactivity than spray-dried particles and milled particles. In addition, the porous nature of the particles provides rapid dissolution properties. The invention is applicable to the formation of other powders, including powder forms of nutraceuticals and foods.
07 Therefore, according t~ an aspect of the invention, there is provided a method of creating a powder, comprising spraying a carrier liquid containing a pov~der forming ingredient to forth a flow of liquid droplets; entraining the flow with a coolant for sufficient time to freeze the liquid droplets into frozen particles; and drying the frozen particles to fbrm a dry powder.
08 According to a further aspect of the invention, there is provided apparatus for atmospheric spray freeze drying of an ingredient carrying liquid to form a powder, the apparatus comprising: a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid t~ produce a flow of liquid droplets; a nozzle system for providing a flow of coolant that entrains atomized fluid sprayed by the atomaizer; a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the fl~w of coolant before contact with the collector.
09 The powder forming ingredient may be suspended or dissolved in the carrier liquid. 'The entraining flow may be a concurrent flow of coolant, for example as sprayed from a ring nozzle or through porous side walls of a confining chamber. Frozen particles are preferably collected on a filter at an exit from the confining chamber, and drying mostly takes place on the filter. For enhanced drying, the flow over the filter should be at a warmer temperature than for freezing.
More than one powder forming ingredient may be l3resent in the carrier liquid.
Other aspects of the invention appear in the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
11 There will now be described preferred embodiments of the irmention with reference to the figures, by way of example, and without intending to limit the scope of the invention to the precise examples disclosed here, and in which figures:
Fig. 1 shows a first embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention;
Fig. 2 shows a second embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention; and Fig. 3 shows a third embodiment of a device for accomplishing atmospheric spray freeze drying according to the invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENT S OF THE INVENTION
12 The word "comprising" in the claims is used in its inclusive sense and does not exclude other elements being present. The use of the indefinite article "a" in a claim before an element does not exclude more than one ofthe element being present.
13 The present invention is widely applicable for producing particulate material and can be used for spray-freeze drying any material amenable to dissohztion or suspension in a suitable carrier liquid, such as water. The term powder forming ingredient is used to refer to one or more pharmaceutical, nutraceutical, food or other substances that have utility in powder form. 'The present invention is especially useful for heat-sensitive substances, such as proteins, nucleic acids, oligonucleotides, enzymes, liposomes, lipids, lipid complexes, anti-virals and vaccines (e.g. involving nonvirulent or attenuated pathogens), carbohydrates, polymers, polysaccharides, and peptides. However, its use is not limited to only large molecules, since the Yraethod always produces a powder from any material dissolved or suitably suspended in water;
it may be used to create, for example, powder anti-infectives, anti-microbials, anti-inflammatories, antineoplastics, analgesics, anaesthetics, cholinergics, adrenergics, anticonvulsants, anti-depressants, sedatives, tranquilizers and antiemetics, ixnmunosuppressives and immunostimulants, antihistamines, hormones, antivenoms and antitoxins. Cryoprotectants may be added to aid in preventing degradation of substances during processing. 'The ingredient carrying liquid may contain several different drugs arid also excipient material. For example, the particles may be made mostly out of lactose with only a little drug in them. Gr there may be several drags in the ingredient carrying liquid, plus lactose or other filler/matrixJexcipient compound.
14 In the embodiments shown in Figs. l, 2 and 3, a flow or spray of atomized carrier fluid is frozen into a powder of solid particles by an entraining flow of coolant and subsequently dried by providing a flow of desiccating gas over the powder. Entraining by the cooling gas provides for confining the spray, and immediate freezing of the individual spray droplets, so that the liquid spray droplets do not impact on the walls of the chamber in which the process is carried out.
15 Referring to the first eanbodiment shown in Fig. 1, a housing 100 formed with solid insulated walls supports at an inlet end an atomizer 102 that is supplied through line 104 with compressed gas from source 106 and a suitable carrier liquid from source I08.
Inside the housing 100 is a flow chamber A 10 with porous walls. 'The flow chamber 110 is formed of cylindrical sections 112, 114 of differing diameter joined by a, con.icai section 116. Multiple nozzles 118 of a nozzle system penetrate the housing 100 arid supply a cryogenic flow of coolant from a coolant source 120 into the space between the housing 100 and flow chamber 110. At the other, exit, end of the housing 100 from the atomizer 102, the ~:'!ow chamber 110 terminates in a filter 122 that is held across an opening in the housing 100 by ~ plate 124 fixed to the chamber 100 by bolts or clamps 126 with ~-ring i28. Gas flow from the exit end of the housing 100 is returned to a refrigerated condenser that forms part of the coolant souxce 120. The refrigerated condenser strips moisture from the cooling gas for re-use of the cooling gas.
16 Referring to a second embodiment shown in Fig. 2, a housing 200 formed with solid insulated walls supports at an inlet end an atomizer 202 that is supplied through line 204 with compressed gas from source 206 and a suitable carrier liquid from source 208.
Inside the housing 200 is a flow chamber 210 defined by solid walls lining the housing 200. The flow chamber 210 is formed of cylindrical sections 212, 214 of differing diameter joined by a conical section 216. Surrounding the atomizer 202 is a nozzle system in the form of a ring nozzle 218, with openings 219 directing flow from the ring nozzle 218 parallel to flow from the atomizer 202. The ring nozzle 218 supplies a cryogenic flow of coolant from a coolant source 220, for example a Iiquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 202 in the spray-freezing step and a refrigerated condenser in the following drying step.
At the other, exit, end of the l~.ousing 200 from the atomizer 202, the flow chamber 210 terminates in a filter 222 that is held across an opening in the housing 200 by a plate 224 fixed to flanges 225 on the chamber 200 by bolts or clamps 226 with O-ring 228.
17 Referring to a third embodiment shown in fig. 3, a housing 300 formed with solid insulated walls supports at an inlet end an atomizer 302 that is supplied through line 304 with compressed gas from source 306 and a suitable carrier liquid from source 308.
Inside the housing 300 is a cylindrical flow chamber 310 defined by solid walls lining the housing 300.
Surrounding the atomizer 302 is a ring nozzle 318, with openings 319 directing flow from the ring nozzle 318 parallel to flow from the atomizer :302. T'he ring nozzle 318 supplies a cryogenic flow of coolant from a coolant source 320, for example a liquid nitrogen cylinder driven by compressed gas that surrounds flow from the atomizer 302 in the spray-freezing step and a refrigerated condenser in the following drying step. At the other, exit, end of the housing 300 from the atomizer 302, the flow chamber 310 terminates in a filter 322 that is held across an opening in the housing 300 by a plate 324 fixed to flanges 32~ on the chamber 300 by bolts or clamps 326 with O-ring 328.
18 The coolant source 120, 220 or 320 nay be any source of a coolant that does not contaminate or degrade the powder. Cold gas may be used such as refrigerated nitrogen, particularly for the embodiment shown in Fig. 1. The nitrogen may also be obtained from a liquid nitrogen cylinder driven by compressed gas, particularly for the embodiment shown in Figs. 2 and 3. Upon exiting the nozzles 118, 218 and 318, cold gas or liquid, for example cold liquid nitrogen or cold gaseous nitrogen, which may be sourced from a cylinder of liquid nitrogen or other cryogenic source of nitrogen, will entrain the spray and freeze the liquid drops of the spray. For freezing followed by drying, both a liquid nitrogen source and a refrigeration unit may be used. Freezing may be carried out using the liquid nitrogen source, as in the embodiment of Figs. 2 and 3, and then drying may be carried out at warmer temperatures using the refrigeration unit.
19 During manufacture, pharmaceutical agents (PA) or other powder forming ingredients are mixed with a carrier liquid prior to spraying from the atomizer 102, 202, 302.
The spray fluid resulting from the mixture of PA sand carrier liquid may be, for example, a solution, a suspension or a colloid. The atomizer 102, 202, 302 may be a two-fluid nozzle or an ultrasonic nebulizer or a vibrating orifice aerosol generator (VGAG) or other atomizing device. The spray fluid, which is formed of liquid droplets, is rapidly frozen through contact with coolant, which is a cold fluid of a suitable temperature. In the spray-freeze step, cooling fluid may be supplied in several possible ways. ~ne way, shown in Figs. 2, 3, is to spray cooling liquid such as liquid nitrogen directly into the chamber 200,300 by using the ring nozzle 218, 318, while spray droplets from atomizer 202, 302 inside the perimeter of the ring nozzle 218, 318 are frozen immediately after contacting the surrounding curtain of liquid nitrogen and then conveyed to the exit filter 222, 322 at the exit end of the housing 200, 300. Another way, shown in Fig. I, is to have a cooling gas enter through porous walls 112, 114, 116 that enclose the atomizer 102. Gas supplied into the space between the housing I00 and chamber 1I0 forms a gas jacl~et whose temperature is adjusted by mixing with liquid nitrogen or an equivalent cryogenic at different ratios.
20 In the example of Figs. 2 and 3, the curtain of spraying liquid nitrogen is used for freezing the spraying liquid droplets and avoiding cohesion oi" frozen powder on the sidewalk 210, 310. The spraying velocity and quantity of liquid nitrogen is controlled to meet both the cooling demand of the spray-freeze process and conveying of frozen powders to the exit filter 222, 322. In the example of Fig. 1, the flow passing through the porous sidewalk of the freezing chamber 110 has the same function as the spraying curtain of liquid nitrogen, i.e. reducing the particle cohesion and allowing a distinguishangly radial flow of cooling fluid into the chamber 110 to freeze liquid droplets and protect the liquid droplet/fro:zen particles from contacting the wall surface. The thickness of the porous sidewall 110 and pressure inside the gas jacleet, which is controlled by the flow rate of cooling gas into the chamber 100, are adjusted for the particular powder being processed. Thereafter, a down-flow transport by ~~irtue of the spray direction of the atomizer 102 is automatically formed in the spray-freeze process to carry all the frozen powder to the exit end of the chamber 100.
2 i After the accomplishment of spray-freezing, a proper drying temperature will be chosen in a drying step by flow rate adjustment from the cooling cryogenic or refrigeration system. In the meantime, the initial frozen powder collected on the exit filter 122, 222, 322 at exit end (bottom) of the chamber will be dried by sublimation in a cold desiccated airstream at atmospheric pressure.. Because all the frozen powder falls down or is conveyed by the down stream flow to the exit filter, no matter whether it is cohesive powder or free flow powder, no external forces are needed to re-lift the powder adhering on the walls, unlike in the spray-freeze drying process of a traditional up-stream fluidized bed, which are used in other processes like US
Patent 4,608,764.
22 In addition, less contamination is realized through this invention by screening frozen powder from contacting the sidewalk of the chamber 110, 21.0, 310 compared to the former technology. As the sublimation process is taking place, the frozen particles become lighter and the aerodynamic behavior changes. The partially dried particles may form a loose cake on the exit filter 122, 222, 322, from which the remaining moisture is removed by atmospheric sublimation using a cold desiccated gas stream, resulting in final free-flowing powders. After spray-freeze atmospheric drying, dry porous particles of xoughly the same size and shape as the original frozen droplets are obtained.
23 Spray freeze atmospheric dried particles produced by this method can have a morphology desirable for respiratory administration of medicament using respiratory delivery devices such as those disclosed in United States Patent Application US60430085 filed Nov. 27, 2003. The typically porous nature of particles formed from this process is also desirable for rapid dissolution, as seen in the BioAqueous technology from I7ow Cb.emical Company, as well as for other purposes such as those disclosed in e.g. United States Patent No.
6,635,283.
OPERATING PROCEDURES
24 The apparatus is allowed to run for approximately 5 to 30 minutes to reach the desired temperature in the chamber I 10, 210, 3I0 either by spraying liquid nitrogen directly into it, or by having the cold fluid from a refrigeration system flow into the chamber 110 through the porous wall. The aqueous solution or suspension of the substances to be dried is then sprayed using the atomizer 102, 202, 302 and frozen simultaneously in situ at a chosen temperature by the surrounding curtain of liquid nitrogen generated from ring nozzle 218, 318 or an equivalent such as cryogenic flow from nozzles 118 through porous sidewalk of chamber 110. The frozen powder is conveyed down to the exit filter I22, 222, 322 by the concurrent downstream flow.
After completion of the spray-freezing process, the flow of the cryogenic flLiid (at a low temperature of -50°C to -196°C) is shut off and switched to a cooling gas at a somewhat higher temperature (-10°C to -30°C) from the refrigeration system. Then the frozen powder collected on the exit filter 122, 222, 322, at the bottom is dried continuously by sublimation at atmospheric pressure until the remaining moistrare of the frozen powder is removed by the cold desiccated gas stream. After spray-freeze atmospheric drying, a noose cake occurs on the exit filter 122, 222, 322, which is very fragile and easily broken into free flowing, dry porous particles of approximately the same size and shape as the original frozen droplets. In order to reduce moisture condensation on the cold particle surface, the temperature of the desiccant cooling gas will be raised to room temperature gradually before the sample is collected from the chamber 100, 200, 300.
25 In one example, powder was produced using the method described above. A
l5wt%
mannitol solution was spray freeze-dried using the apparatus shown in Fig. 1.
A 15 % mannitol (Mannitol USP powder, Fisher Scientific) aqueous solution was used to demonstrate the process.
Before spraying, the chamber 110 for spray-freeze drying was allowed to nzn for approximately 20 minutes to reach the desired tegnperature (-65°C). During the 20 minutes, the cold fluid from a refrigeration unit incorporating two parallel dry-ice cooling columns flows into the chamber IIO through the porous sidewall. A Chem-Tech pump (Model CTPA4LSA-PAPI-XXXX, Viking pump of Canada Inc, Windsor, Ontario, Canada) was used to pump 20 mI of 15%
mannitol solution into an air atomizing spray nozzle 102 (Spraying Systems Co., Wheaton, Illinois, USA) spraying into the chamber from the top with the aid of a compressed driving gas (nitrogen) at a flowrate of 0.6 SCF1VI. The spray-freezing process was finished within 4 minutes and meanwhile, the temperature in the chamber 110 was kept at -50°C to -70°C by the mixed cooling gas (nitrogen). In this case, the pressure in the chamber was almost atmospheric (around 1.02 atm). After the completion of spray-freeze process, the pump and driving gas for spraying was shut down and the cooling gas for drying was kept Ilowir~g at a flowrate of 60 L/min. The temperature in the chamber was kept at around -lj°C (-~°C to -20°C) by adjusting the height of dry ice in the cooling columns. After drying for 1 hr, the temperature in the chamber was raised to room temperature gradually within another 30 minutes at a flowrate of 30 L/min. T hereafter, the cooling gas was shut off and a dry powder cake on the exit filter 122 was collected. This sake was easily broken into a free-flowing po order and the resulting particles were found very porous and roughly spherical. The moisture content was measured to be only 0.9%.
Photos from a scanning electron microscope (S~ll~d) of one resulting sample powder collected from the exit filter showed that the powder particles are relatively spherical and considerably porous, which is often seen in spray-freeze drying with vacuum.
26 Mannitol has been spray-frozen by us at -50°C to -70°C and dried in a temperature of -5°C to -20°C in order to avoid mannitol crystallization (mannitol hydrate occurs at around 38°C).
Based on practical demand (each bio-substance may have its ideal spray-freeze and drying temperature), the spray-freeze drying conditions are adjustable by changing the temperature and flow rate of the mixed cold gases. Depending on the batch scale, these parameters may be different.
27 For atmospheric pressure freeze drying with dry air, the temperature at which material may be truly freeze dried is set by its melting point. Since the vapor presswe of ice is essentially fixed by the melting point temperature, the rate of freeze-drying is essentially controlled by the resistance to water vapor diffusion in the material. This resistance is proportional to the diffusion path length and the permeability of the material. Atmospheric pressure freeze-drying should therefore be feasible in a wide variety of materials where diffizsion distances are very short in materials of open structure.
28 Immaterial modifications array be made to the invention described here without departing from the invention.
Claims (34)
PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method of creating a powder, comprising spraying a carrier liquid into a chamber, the carrier liquid containing a powder forming ingredient to form a flow of liquid droplets;
entraining the flow within a co-current flow of coolant for sufficient time to freeze the liquid droplets into frozen particles, the flow of coolant entering the chamber around the flow of liquid droplets and frozen particles to screen the frozen particles from contacting walls of the chamber; and drying the frozen particles to form a dry powder.
entraining the flow within a co-current flow of coolant for sufficient time to freeze the liquid droplets into frozen particles, the flow of coolant entering the chamber around the flow of liquid droplets and frozen particles to screen the frozen particles from contacting walls of the chamber; and drying the frozen particles to form a dry powder.
2. The method of claim 1 in which the powder forming ingredient is suspended or dissolved in the carrier liquid prior to spraying the carrier liquid into the chamber.
3. The method of claim 1 or 2 in which the co-current flow of coolant is sprayed from a ring nozzle.
4. The method of claim 1 or 2 in which the flow of coolant is injected through porous walls of the chamber.
5. The method of claim 1, 2, 3 or 4 in which the frozen particles are collected on a filter.
6. The method of claim 5 in which the frozen particles are substantially dried after being collected on the filter.
7. The method of claim 1 in which the flow of coolant has a temperature within a first temperature range during freezing of the liquid particles and a temperature warmer than the first temperature range during drying of the frozen particles.
8. The method of claim 1 in which the carrier liquid contains more than one powder forming ingredient.
9. A method of creating a powder within a chamber comprising providing a flow of liquid droplets containing a powder forming ingredient to form a flow of liquid droplets; and treating the liquid droplets with a flow of coolant inside the chamber to freeze the liquid droplets to form frozen particles prior to deposition;
depositing the frozen particles on a collector; and after deposition of the frozen particles, drying the deposited frozen particles, to form a dry powder.
depositing the frozen particles on a collector; and after deposition of the frozen particles, drying the deposited frozen particles, to form a dry powder.
10. The method of claim 9 in which flow of coolant is co-current with the flow of liquid droplets.
11. The method of claim 9 or 10 in which flow of coolant for drying frozen particles is in co-direction with the gravity.
12. The method of claim 9, 10 or 11in which the flow of coolant prevents adherence of liquid droplets to walls of the chamber.
13. The method of claim 9, 10, 11 or 12 in which the flow of liquid droplets contains more than one powder forming ingredient.
14. A method of creating a powder, comprising the steps of:
spraying a carrier liquid containing a powder forming ingredient to form a flow of liquid droplets;
entraining the flow of liquid droplets within a co-current flow of coolant for sufficient time to freeze the liquid droplets into frozen particles;
collecting the frozen particles on a filter, the flow of liquid droplets and frozen particles remaining co-current with the flow of coolant until the frozen particles are collected on the filter;
and drying the frozen particles to form a dry powder.
spraying a carrier liquid containing a powder forming ingredient to form a flow of liquid droplets;
entraining the flow of liquid droplets within a co-current flow of coolant for sufficient time to freeze the liquid droplets into frozen particles;
collecting the frozen particles on a filter, the flow of liquid droplets and frozen particles remaining co-current with the flow of coolant until the frozen particles are collected on the filter;
and drying the frozen particles to form a dry powder.
15. The method of claim 14 in which the powder forming ingredient is suspended or dissolved in the carrier liquid prior to spraying the carrier liquid into the chamber.
16. The method of claim 14 in which the co-current flow of coolant is in co-direction with gravity.
17. The method of claim 14, 15 or 16 in which the co-current flow of coolant is sprayed from a ring nozzle.
18. The method of claim 14, 15 or 16 in which the co-current flow of coolant is injected through porous walls of the chamber.
19. The method of any one of claims 14-18 in which the frozen particles are substantially dried after being collected on the filter.
20. The method of any one of claims 14-19 in which the co-current flow of coolant has a temperature within a first temperature range during freezing of the liquid particles and a temperature warmer than the first temperature range during drying of the frozen particles.
21. The method of any one of claims 14-20 in which the carrier liquid contains more than one powder forming ingredient.
22. The method of any one of claims 1-8 in which the chamber has at least a side wall, an inlet end and an exit end, and in which the flow of liquid droplets is provided at the inlet end of the chamber.
23. The method of any one of claims 9-13 in which the chamber has at least a side wall, an inlet end and an exit end, and in which spraying of the carrier liquid occurs at the inlet end of the chamber.
24. The method of any one of claims 14-20 carried out in a chamber having at least a side wall, an inlet end and an exit end, and in which spraying of the carrier liquid occurs at the inlet end of the chamber.
25. The method of any one of claim 22-24 in which the flow of coolant confines the flow of liquid droplets and the frozen particles in a down-flow transport of particles from the inlet end of the chamber to the exit end of the chamber.
26. The method of claim 25 in which the co-current flow of coolant forms a curtain between the down-flow transport of particles and the at least a side wall of the chamber.
27. The method of any one of claims 1-24 carried out at atmospheric pressure.
28. The method of any one of claims 1-27 in which the powder forming ingredient comprises a heat-sensitive pharmaceutical.
29. Apparatus for atmospheric spray freeze drying of an ingredient carrying liquid to form a powder, the apparatus comprising:
a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid to produce a flow of liquid droplets;
an injection system for providing a flow of coolant that entrains liquid droplets sprayed by the atomizer;
a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the flow of coolant before contact with the collector.
a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid to produce a flow of liquid droplets;
an injection system for providing a flow of coolant that entrains liquid droplets sprayed by the atomizer;
a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the flow of coolant before contact with the collector.
30. The apparatus of claim 29 in which the injection system and atomizer are oriented to provide co-current flows of coolant and liquid droplets.
31. The apparatus of claim 30 in which the injection system comprises a ring nozzle surrounding the atomizer.
32. The apparatus of claim 30 in which the injection system is arranged around a porous wall defining a flow chamber through which the flow of liquid droplets passes.
33. The apparatus of claim 29, 30, 31 or 32 in which the collector is a filter at an exit from the chamber.
34. The apparatus of claim 33 in which the atomizer and collector are at opposed ends of the chamber.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2450779A CA2450779C (en) | 2003-12-22 | 2003-12-22 | Powder formation by atmospheric spray-freeze drying |
EP04802335.2A EP1697035B1 (en) | 2003-12-22 | 2004-12-20 | Powder formation by atmospheric spray-freeze drying |
PCT/CA2004/002160 WO2005061088A1 (en) | 2003-12-22 | 2004-12-20 | Powder formation by atmospheric spray-freeze drying |
JP2006545859A JP5183068B2 (en) | 2003-12-22 | 2004-12-20 | Powder formation by atmospheric spray freeze drying |
US12/050,654 US8322046B2 (en) | 2003-12-22 | 2008-03-18 | Powder formation by atmospheric spray-freeze drying |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2450779A CA2450779C (en) | 2003-12-22 | 2003-12-22 | Powder formation by atmospheric spray-freeze drying |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2450779A1 CA2450779A1 (en) | 2005-06-22 |
CA2450779C true CA2450779C (en) | 2012-10-16 |
Family
ID=34683000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2450779A Expired - Lifetime CA2450779C (en) | 2003-12-22 | 2003-12-22 | Powder formation by atmospheric spray-freeze drying |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2450779C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1798504A1 (en) * | 2005-12-19 | 2007-06-20 | Koninklijke Philips Electronics N.V. | Method of making dried particles |
CN110639427A (en) * | 2018-12-10 | 2020-01-03 | 金昌正旭工贸有限责任公司 | Sulfur molten liquid spraying water-cooling medium granulation process |
-
2003
- 2003-12-22 CA CA2450779A patent/CA2450779C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2450779A1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7007406B2 (en) | Powder formation by atmospheric spray-freeze drying | |
US8322046B2 (en) | Powder formation by atmospheric spray-freeze drying | |
EP1590613B1 (en) | Lyophilization method and apparatus for producing particles | |
EP0742888B1 (en) | Process for drying a material from solution | |
Wanning et al. | Pharmaceutical spray freeze drying | |
Chow et al. | Particle engineering for pulmonary drug delivery | |
Ishwarya et al. | Spray-freeze-drying: A novel process for the drying of foods and bioproducts | |
JP2004517699A (en) | Method for producing nanoparticles and microparticles by spray freezing into liquid | |
US7208106B2 (en) | Method of forming particles | |
JP3942093B2 (en) | Spray type vacuum freeze dryer | |
JP2011006444A (en) | High pressure spray-drying of bioactive material | |
CN209438066U (en) | Ultralow temperature is sprayed vacuum freeze drying formula biology dry powder particles preparation system | |
Rostamnezhad et al. | Spray freeze-drying for inhalation application: process and formulation variables | |
CA2450779C (en) | Powder formation by atmospheric spray-freeze drying | |
US20240151465A1 (en) | Continuous throughput lyophilizer-powder filler within a sterile boundary | |
WO2020161863A1 (en) | Vacuum-freeze drying method and vacuum-freeze drying device | |
Kale et al. | Recent advancements in particle engi-neering techniques for pharmaceutical applications | |
Patil | Spray-drying: an emerging technique for pharmaceutical product development | |
WO2013139384A1 (en) | Freezing of aerosolized solutions (fas): a system for continuous particle production | |
CN206508943U (en) | Porous light particle preparation facilities | |
JP2023057704A (en) | Method for producing granules and method of producing granules containing viable bacteria | |
JP2004230089A (en) | Method for preparing formulation by using depositing particulates | |
IES64140B2 (en) | Process for drying a material from solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20231222 |